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Abstract 20 
Background. Tegumentary leishmaniasis (TL) is a disease of skin and/or mucosal tissues caused by 21 
Leishmania parasites. TL patients may concurrently carry other pathogens, which may influence the 22 
clinical outcome of TL.  23 
Methodology/Principal findings. This review focuses on the frequency of TL coinfections in human 24 
populations, interactions between Leishmania and other pathogens in animal models and human 25 
subjects, and implications of TL coinfections for clinical practice. For the purpose of this review, TL 26 
is defined as all forms of cutaneous (localised, disseminated or diffuse) and mucocutaneous 27 
leishmaniasis. HIV coinfection, superinfection with skin bacteria, and skin manifestations of visceral 28 
leishmaniasis are not included. We searched MEDLINE and other databases and included 68 29 
records: 21 experimental studies in animals, and 47 studies about human subjects (mainly cross-30 
sectional and case studies). Several reports describe the frequency of Trypanosoma cruzi 31 
coinfection in TL patients in Argentina (about 41%), and the frequency of helminthiasis in TL 32 
patients in Brazil (14% to 88%). Different hypotheses have been explored about mechanisms of 33 
interaction between different microorganisms, but no clear answers emerge. Such interactions may 34 
involve innate immunity coupled with regulatory networks that affect quality and quantity of 35 
acquired immune responses. Diagnostic problems may occur when concurrent infections cause 36 
similar lesions (e.g. TL and leprosy), when different pathogens are present in the same lesions (e.g. 37 
Leishmania and Sporothrix schenckii), or when similarities between phylogenetically close 38 
pathogens affect accuracy of diagnostic tests (e.g. serology for leishmaniasis and Chagas disease). 39 
Some coinfections (e.g. helminthiasis) appear to reduce the effectiveness of antileishmanial 40 
treatment, and drug combinations may cause cumulative adverse effects.  41 
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Conclusions/Significance. In patients with TL, coinfection is frequent, it can lead to diagnostic 42 
errors and delays, and it can influence the effectiveness and safety of treatment. More research is 43 
needed to unravel how coinfections interfere with the pathogenesis of TL.  44 
 45 
Author summary 46 
Infectious diseases are often studied one by one, but people can have more than one 47 
infection at the same time. This is likely to happen when different microorganisms are linked to 48 
specific geographical regions or living conditions. In this paper, we summarise the literature about 49 
infections occurring together with tegumentary leishmaniasis, a disease of skin and mucosal tissues 50 
that is caused by Leishmania parasites. We found that in Latin America, patients with tegumentary 51 
leishmaniasis are often also infected with helminths or with Trypanosoma cruzi (the parasite that 52 
causes Chagas disease). Information from other parts of the world is scarce. Animal studies and 53 
observations in humans show that one infection can change the course of another infection, but 54 
how this happens is not well understood. When different infections affect the same patient at the 55 
same time, the diagnosis can be difficult, especially when different microorganisms are biologically 56 
similar, when they cause similar lesions, or when they are present in the same lesions. Treatment 57 
can also be difficult because some coinfections reduce the efficacy of the treatment against 58 
Leishmania, and because some drug combinations can lead to cumulative adverse effects. 59 
  60 
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Introduction 61 
Tegumentary leishmaniasis (TL) is a disease of the skin and mucosal tissues caused by 62 
several species of the genus Leishmania (Protozoa, Trypanosomatida, Trypanosomatidae) that are 63 
transmitted by the bite of phlebotomine sandflies [1]. Parasites belonging to the sub-genus 64 
Leishmania are found in the Old and the New World, whereas those of the sub-genus Viannia are 65 
restricted to the New World [1-3]. Leishmania parasites produce a wide spectrum of clinical 66 
manifestations in humans and other mammals, ranging from asymptomatic infection to life-67 
threatening disease [1-3]. Yearly, an estimated one million people develop TL, mainly in Bolivia, 68 
Brazil, Colombia, Peru, Algeria, Tunisia, Saudi Arabia, Syria, Iran, Afghanistan, and Pakistan [4].  69 
The overlapping geographical distribution of TL with many highly prevalent (e.g. 70 
helminthiasis) [5] and some less common (e.g. leprosy) [6] infectious diseases, as well as 71 
experimental studies [7], together indicate the importance of understanding how coinfections may 72 
alter the outcome of TL and vice versa. Indeed, several infectious diseases linked to poverty, 73 
housing conditions, hygiene, or to vectors that thrive in similar circumstances tend to affect the 74 
same populations [8-12]. It is, therefore, likely that in the tropical and temperate regions where TL 75 
occurs, many people carry more than one pathogen at once, although the epidemiology of such 76 
coinfections is not well known. Furthermore, the clinical outcome of Leishmania infection depends 77 
on characteristics of both the Leishmania parasite and the human host immune response [13-16]. 78 
Pathogens other than Leishmania may modulate this host immune response and consequently, 79 
influence the natural history of TL as well as the response to anti-leishmanial treatment [12,16].  80 
The most frequently studied coinfection is that between Leishmania and human 81 
immunodeficiency virus (HIV), where the natural history of each of the two infections is modified by 82 
the presence of the other [17]. HIV increases the risk of severe and disseminated TL, and some HIV-83 
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infected patients develop visceral leishmaniasis in the presence of Leishmania species that are 84 
usually only dermotropic [17-19]. HIV also increases the risk of TL recurrence and treatment failure 85 
[18,19]. On the other hand, leishmaniasis interferes with monocyte and macrophage function in 86 
such a way that it facilitates HIV progression [20]. Interactions between TL and infections other 87 
than HIV have not been comprehensively reviewed before.  88 
The objectives of the present review are to summarise the evidence about the (i) frequency 89 
of TL and coinfections other than HIV in human populations, (ii) interactions between Leishmania 90 
and other pathogens in animal models and human subjects, and (iii) implications of TL coinfections 91 
for clinical practice. 92 
 93 
Methods 94 
Eligibility criteria 95 
We searched the medical literature to identify publications about TL and coinfections. For 96 
the purpose of this review, we defined TL as all forms of cutaneous (localised, disseminated or 97 
diffuse) and mucocutaneous leishmaniasis. Records about the skin manifestations caused by L. 98 
donovani and L. infantum/L. chagasi (such as post-kala-azar dermal leishmaniasis) were not 99 
included because the main clinical outcome of these infections is visceral leishmaniasis, which is 100 
outside the scope of this review.  101 
Records about HIV/AIDS and TL were not included because this topic has already been 102 
extensively reviewed elsewhere [17-19]. Records about the contamination or superinfection of TL 103 
lesions with Gram-positive or Gram-negative bacteria of the skin such as Staphylococcus aureus or 104 
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Streptococcus pyogenes were also excluded. Review papers were not included. We did not restrict 105 
the search by geographical region, study design, language of publication or publication date.  106 
 107 
Information sources and search 108 
The databases MEDLINE, Embase, LILACS, Scielo, Cochrane, African Index Medicus, as well 109 
as local library databases, searched in August 2017, were the information sources for this review. 110 
We used search terms indicating (groups of) infections, pathogens, and diseases caused by these 111 
pathogens. The detailed search strategy for MEDLINE is given in S1 File. We also reviewed the 112 
reference lists of selected articles.  113 
 114 
Data collection and synthesis 115 
Two reviewers extracted the data from the included records; any doubts and discordances 116 
were resolved through discussion. Specific points of interest while reading and summarising the 117 
articles were: (i) frequency of coinfection in humans; (ii) mechanisms of interaction and effect of 118 
coinfection on TL progression; and (iii) potential implications for clinical management. We 119 
described the information the same way the authors of the original publications did, using mainly 120 
counts, proportions and medians. 121 
We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 122 
statement [21] to prepare this review, but it was not possible to follow all the recommendations 123 
because PRISMA mainly focuses on the evaluation of health care interventions and our focus was 124 
broader than that. The PRISMA checklist is given in S2 List.  125 
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 126 
Results 127 
Study selection and characteristics 128 
The MEDLINE search retrieved 669 records and searching other databases yielded 348 129 
additional records. After reading titles or abstracts or both, we removed 79 duplicates and 130 
discarded 841 records because they were not relevant (Fig 1). The most frequent reason for 131 
dropping records was that while leishmaniasis and another infection were mentioned in the same 132 
text, the publication was not about coinfection (e.g. a paper about different infections occurring in 133 
the same region but not affecting the same persons). We assessed the remaining 97 full-text 134 
records for eligibility and retained 73 for the present review (Fig 1).  135 
Fig 1. Flow diagram of record search and selection. 136 
The 73 articles included in this review had different study designs (Table 1). There were 21 137 
original research papers about experimental studies of coinfection in animal models, and 52 original 138 
research papers about coinfection in human patients. The 52 studies about human subjects 139 
included 1 clinical trial, 2 cohort studies, 13 cross-sectional or prevalence studies, 7 studies on the 140 
development or performance of diagnostic tests, 24 case series or case reports with a clinical focus, 141 
and 5 case series or reports with an immunological focus. The coinfecting pathogens for which we 142 
found the highest number of records were Trypanosoma cruzi (n=18), Mycobacterium leprae 143 
(n=14), helminths (n=12), and Mycobacterium tuberculosis (n=9). Two records addressed 144 
coinfection of Leishmania with more than one pathogen (Table 1). 145 
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Table 1. Overview of all studies about tegumentary leishmaniasis and coinfections included in this review 146 
Coinfecting pathogen Study design Number of 
studies 
Number of human 
cases with coinfection 
References to 
included studies 
Helminths     
Ancylostoma duodenale, Ascaris lumbricoides, 
Schistosoma mansoni, Strongyloides 
stercoralis, and/or Trichuris trichiura 
Randomised clinical trial 1 90 [22] 
Ancylostoma duodenale, Ascaris lumbricoides, 
Schistosoma mansoni, Strongyloides 
stercoralis, and/or Trichuris trichiura 
Cohort study 2 122 [5,12] 
Litomosoides sigmodontis, Nippostrongylus 
braziliensis, Schistosoma mansoni, 
Strongyloides ratti or Taenia crassiceps  
Experimental study in animals 8 Not applicable [7,23-29] 
Protozoa     
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Trypanosoma cruzi Cross-sectional study in general population 1 11 [30] 
Trypanosoma cruzi Cross-sectional study in TL patientsa 7 211a [31-37] 
Trypanosoma cruzi Study about diagnostic testsa 6 74a [38-43] 
Trypanosoma cruzi Immunological study in humans 1 16 [44] 
Trypanosoma cruzi Case report/series 1 1 [45] 
Trypanosoma cruzi Experimental study in animals 2 Not applicable [46,47] 
Trypanosoma brucei Experimental study in animals 2 Not applicable [48,49] 
Toxoplasma gondii Cross-sectional study in TL patients 1 2 [37] 
Toxoplasma gondii Immunological study in humans 1 16 [50] 
Toxoplasma gondii Experimental study in animals 2 Not applicable [51,52] 
Plasmodium sp. Experimental study in animals 7 Not applicable [53-59] 
Fungi     
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Sporothrix schenckii Case report/series 2 4 [60,61] 
Sporothrix schenckii Study about diagnostic tests 1 0 [62] 
Paracoccidioides braziliensis Cross-sectional study in TL patients  1 2 [37] 
Paracoccidioides braziliensis Cross-sectional study in patients with 
paracoccidioidomycosis 
1 10 [63] 
Coccidioides posadasii Cross-sectional study in TL patients 1 1 [37] 
Cryptococcus laurentii Case report/series 1 1 [64] 
Mycobacteria     
Mycobacterium tuberculosis Cross-sectional study in TL patients 1 3 [37] 
Mycobacterium tuberculosis Case report/series 8 9 [65-72] 
Mycobacterium leprae Case report/series 12 25 [6,70,73-82] 
Mycobacterium leprae Case report/series of leprosy patients 
immunised with live Leishmania tropica 
2 0 [83,84] 
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Mycobacterium ulcerans Case report/series 1 1 [85] 
Other bacteria     
Treponema pallidum Cross-sectional study in TL patients 1 4 [37] 
Burkholderia pseudomallei Case report/series 1 1 [86] 
Viruses     
HTLV-1 Cross-sectional study in TL patients  3 2 [87-89] 
HTLV-1 Cross-sectional study in HTLV-1-infected 
subjects 
1 8 [90] 
TL: tegumentary leishmaniasis; HTLV-1; human T-lymphotropic virus 1  147 
aSome overlap is possible because several papers come from the same research group. 148 
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Frequency of TL coinfections in human populations 149 
The studies providing information about the frequency of coinfection in human populations 150 
are summarised below and in Table 1.  151 
 152 
Leishmania and helminths. Two Brazilian cohort studies describe the frequency of helminth 153 
infections in patients with TL [5,12]. The first study recruited 120 patients with TL in a village health 154 
post in a rural area of Bahia state [5]. Only patients with cutaneous forms of leishmaniasis were 155 
included (maximum four lesions on maximum two body regions). The Leishmania species was not 156 
determined, but the predominant species in this region is known to be L. braziliensis. Study 157 
participants provided three stool samples for parasitological assays (sedimentation, Baermann, and 158 
Kato-Katz methods). One hundred six (88%) of the 120 patients with TL were diagnosed with a 159 
helminth infection. Seventy-three percent of the study participants were infected with more than 160 
one helminth species at the same time. The most common helminths in this study were 161 
Ancylostoma duodenale, Trichuris trichiura, Ascaris lumbricoides, Schistosoma mansoni, and 162 
Strongyloides stercoralis.  163 
The second study was done in an urban area in the state of Rio de Janeiro [12]. This was a 164 
retrospective cohort study of 109 TL patients who received antimony therapy in a referral centre 165 
between 2004 and 2006: there were 99 cases of cutaneous and 10 of mucocutaneous 166 
leishmaniasis. All included patients had a parasitologically confirmed diagnosis of leishmaniasis. The 167 
species was typed in samples from 47 patients; they were all L. braziliensis. Parasitological 168 
examination of stool samples using sedimentation, Kato-Katz and Baermann-Moraes methods was 169 
routinely performed during the study period. Fifteen (14%) out of 109 TL patients had helminth 170 
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infections. The most frequent helminths were Ancylostomidae, Ascaris lumbricoides, Strongyloides 171 
stercoralis, Schistosoma mansoni, and Trichuris trichiura [12].  172 
 173 
Leishmania and other Trypanosomatidae. The existence of coinfection with Trypanosoma cruzi 174 
was proven in Argentina in 1996 [33]. Seven (58%) out of twelve patients with TL were diagnosed 175 
with T. cruzi infection based on specific serological tests. In three of the seven coinfected patients, 176 
the presence of T. cruzi could be proven with a direct parasitological technique (i.e. xenodiagnosis 177 
using Triatoma infestans nymphs). Six additional studies confirmed, based on specific serological 178 
and molecular techniques that T. cruzi coinfection is frequent in TL patients from Salta, northern 179 
Argentina [31, 34-37,43], where the seroprevalence of T. cruzi in rural populations is estimated to 180 
range between 4% and 30% [31,91]. In all these studies, the coinfected patients had clinical TL but 181 
no signs of cardiac abnormalities typical of Chagas disease at the time of recruitment. The largest 182 
study included 330 patients with TL caused by L. braziliensis or L. amazonensis and found 183 
coinfection with T. cruzi in 135 (41%) of them [36].  184 
Coinfection with T. cruzi has also been found in other Latin American countries 185 
[30,32,39,40]. One study in a hospital in Los Yungas in Bolivia recruited 28 patients with TL caused 186 
by L. braziliensis complex, L. mexicana complex, or both and obtained positive PCR results for T. 187 
cruzi in 22 (79%) [32]. In Paraguay, 8 (8%) out of 101 patients with clinical TL coming from the 188 
Caazapá and Alto Paraná departments were suspected of carrying T. cruzi [39].  189 
The largest prevalence study was done in Brazil and reported on the frequency of 190 
coinfection of L. braziliensis, L. infantum (syn. L. chagasi), and T. cruzi in a sample of 1100 191 
apparently healthy people living in fast-growing villages in the outskirts of São Luiz City, the capital 192 
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of Maranhão State [30]. Diagnosis of Leishmania and Trypanosoma infections was based on 193 
serology and molecular testing of blood samples. Forty-one subjects (4%) were diagnosed with L. 194 
braziliensis infection only, 35 (3%) with T. cruzi only, 50 (5%) with L. chagasi only, 17 (2%) had L. 195 
braziliensis together with L. chagasi, 7 (1%) had L. chagasi together with T. cruzi, and 11 (1%) had L. 196 
braziliensis together with T. cruzi. None of the study participants had signs of past or present TL, 197 
visceral leishmaniasis or Chagas disease. 198 
 199 
Leishmania and human T-lymphotropic virus 1 (HTLV-1). Three small studies in Colombia, Peru, 200 
and Iran reported a low frequency of HTLV-1 infection in patients with TL. The number of study 201 
participants with TL ranged from 4 to 92 and the frequency of HTLV-1 infection ranged from 0% to 202 
4% in subgroups with different forms of TL (subclinical or clinical,  acute or chronic) [87-89]. A 203 
fourth study, from Mashhad in Iran also failed to confirm a clear link between these two infections. 204 
These authors reported that 8 out of 100 HTLV-1-infected candidate blood donors mentioned a 205 
history of cutaneous leishmaniasis, which was not significantly different from the frequency 206 
reported by 100 HTLV-1-negative candidate blood donors [90]. 207 
 208 
Leishmania and other pathogens. One study from Salta in northern Argentina looked into several 209 
coinfections at the same time [37]. In a series of 93 patients with parasitologically confirmed 210 
cutaneous (n=50) or mucocutaneous (n=43) leishmaniasis, 37% had one or more coinfection, i.e. 211 
intestinal parasites (n=2), T. cruzi (n=25), Toxoplasma gondii (n=2), Paracoccidioides brasiliensis 212 
(n=2), Coccidioides posadasii (n=1), Mycobacterium tuberculosis (n=3), and/or Treponema pallidum 213 
15 
 
(n=4). The authors described that the frequency of coinfections was higher in patients with mucosal 214 
forms of leishmaniasis than in those with cutaneous leishmaniasis [37].  215 
Our search retrieved no studies on the frequency of other coinfecting pathogens in TL 216 
patients or the general population, although there were some case reports and series. Therefore, 217 
we can only report on the absolute number of human cases with coinfection mentioned in the 218 
literature. We found reports of 16 cases of concurrent coinfection of Leishmania with Toxoplasma 219 
gondii, 4 with Sporothrix schenckii, 10 with Paracoccidioides brasiliensis, 1 with Cryptococcus 220 
laurentii, 9 with Mycobacterium tuberculosis, 25 with Mycobacterium leprae, 1 with Mycobacterium 221 
ulcerans, and 1 with Burkholderia pseudomallei (Table 1). 222 
 223 
Interactions between Leishmania and other pathogens in animal models and human subjects 224 
Types of interaction. Coinfections may influence the immune response during TL in several 225 
different ways: through actions on local phagocytes, innate immune mechanisms, the balance 226 
between effector and regulatory T-cell subsets, and the capacity of macrophages to kill Leishmania 227 
amastigotes (Fig 2).  228 
Fig 2. Immune responses during tegumentary leishmaniasis and the potential for interference 229 
through coinfection: a means to focus new research. Panel A. Leishmania parasite transmission 230 
during sandfly bite initiates TL. Local phagocyte function (including neutrophils, macrophages, and 231 
dendritic cells) may be affected by coinfections affecting skin homeostasis. Furthermore, 232 
coinfection may affect the nature of pre-existing immunity to sandfly saliva and/or the local 233 
response to sandfly/parasite proteins. Panel B. Innate immune mechanisms regulated by stromal 234 
cells, dendritic cells, and innate lymphoid cells may all be influenced by the microenvironment 235 
16 
 
created by local or systemic coinfection. Panel C. Changes to innate immunity or immunological 236 
cross-reactivity may influence the balance between effector (Th1, Th2 and Th17) and regulatory (R) 237 
T-cell subsets, leading to altered control of parasite load and/or altered immunopathology. Panel D. 238 
Coinfections may directly or indirectly alter macrophage intracellular signalling, affecting the 239 
intracellular survival of Leishmania independently of any effects on the specific T-cell response. 240 
 There is considerable evidence supporting the roles of various key phagocyte populations 241 
(dermal macrophages, monocyte-derived macrophages and dendritic cells, and neutrophils) in the 242 
establishment of infection and first-line defence against Leishmania [92]. There is also a growing 243 
body of literature indicating that the functional attributes of these phagocytes can be influenced by 244 
products introduced during transmission (e.g. sandfly salivary proteins or parasite-derived 245 
immunomodulators) [93-95] or by changes in skin homeostasis (e.g. driven by pathologic 246 
coinfection or changes to the commensal microbiota) [96,97]. One study in mice showed that 247 
resident skin commensals were critical to promoting protective effector T-cell responses to L. major 248 
[98], and thus act as potent immunomodulatory coinfections necessary for the control of TL. 249 
However, specific publications about how phagocytes engaged in TL control may be affected by 250 
other pathogens or skin microbiota are currently lacking. Likewise, coinfection-associated changes 251 
in the function of innate lymphoid cells or mesenchymal stromal cells, although readily predicted 252 
from the literature, have yet to be shown to be relevant in established models of TL. 253 
 A well-known paradigm in immunity relates to the opposing effects of interferon-gamma 254 
(/&Eɶ ?ĂŶĚinterleukin-4 (IL-4) with regard to control of L. major lesion development in mice 255 
[99,100]. Whereas C57BL/6 mice self-heal under the control ŽĨ/&Eɶ ? BALB/c mice succumb to 256 
Leishmania infection in an IL-4-dependent manner. These counter-acting cytokines were identified 257 
as the products of different subsets of CD4+ T helper cells (Th1 and Th2). The finding that these Th 258 
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subsets/cytokines have different roles in the control of helminth versus Leishmania infection led to 259 
the notion that differing infections may skew T-cell immunity in polarised directions [100,101]. 260 
The included studies that contribute information about the interactions between 261 
Leishmania and specific other pathogens are summarised below per coinfecting agent. Most of 262 
these reports are based on research in animal models (n=22), while only a few (n=5) provide an 263 
extensive immunological characterisation of human coinfection. Most of the possible interaction 264 
mechanisms outlined in figure 2 have not been covered yet by the specific literature about TL and 265 
coinfections included in this review.  266 
 267 
Helminths. The effect of helminth coinfection on the course of TL has been studied in mice models 268 
[7,23-29] and described in human patients [5,12,22], with mixed findings. Some of the studies in 269 
mice concluded that in the presence of helminth infection, the time between experimental 270 
infection with Leishmania and development of skin lesions increased [26,27], while others found 271 
that this pre-patent period decreased [23] or remained unchanged [28]. The conclusions were also 272 
divided about the size of the TL lesions, finding larger [7], smaller [27], or similar lesions [25,28] in 273 
mice with helminth coinfection. One study with extended follow-up (16 weeks) showed that the 274 
impact of helminth coinfection on lesion growth was time-dependent [26]. These divergent findings 275 
may be partly due to the parasites used in the experiments (Schistosoma mansoni or Litomosoides 276 
sigmodontis, with L. mexicana or L. major) and the time between the two experimental infections 277 
[23,26,27]. 278 
When it comes to explaining the effects of helminth coinfection on the course of TL, one 279 
experimental study suggested that the Th2 responses induced by helminth infection had systemic 280 
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effects that down-regulated the initial, local Th1 response to Leishmania [26]. In contrast, several 281 
other studies found that helminth infection did not interfere with the generation of Leishmania-282 
specific Th1-type responses [24,25,27-29]. Furthermore, two groups used in vitro models to show 283 
that macrophages from helminth-infected mice were impaired in their ability to kill Leishmania 284 
[7,26]. Three studies in mice also evaluated whether TL altered the course of helminth infections, 285 
but no measurable effect was reported [24,26,28].  286 
Two cohort studies in Brazil compared the characteristics of TL in patients with and without 287 
helminthiasis [5,12]. The studies were conducted in Rio de Janeiro and Bahia, where L. braziliensis is 288 
predominant and pentavalent antimony is the recommended treatment. The study in Bahia 289 
enrolled 120 patients with cutaneous forms of TL (including 106 (88%) with helminthiasis) and the 290 
study in Rio de Janeiro enrolled 109 patients with cutaneous and mucocutaneous forms of TL 291 
(including 16 (15%) with helminthiasis). The helminths detected were Ancylostoma duodenale, 292 
Trichuris trichiura, Ascaris lumbricoides, Schistosoma mansoni and Strongyloides stercoralis. Both 293 
studies reported that the time to heal under pentavalent antimony treatment was longer for 294 
patients with TL and helminth infection than for patients with TL only [5,12]. The study in Rio de 295 
Janeiro also found significant associations of helminth coinfection with mucosal leishmaniasis and 296 
poor response to treatment [12].  297 
 298 
Trypanosoma. Four experimental studies (in mice or squirrel monkeys) and one observational study 299 
in humans addressed the effect of Trypanosoma coinfection (T. brucei or T. cruzi) on TL [46-49]. 300 
Experimental Chagas disease did not protect against leishmaniasis and vice versa [46], although 301 
there were elements of immune cross-reactivity [47]. For the studies evaluating the impact of 302 
Trypanosoma on time until Leishmania lesion development [46-49], the main finding was a 303 
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reduction in lesion growth rate in coinfected animals. In some cases, protection from ulceration 304 
was reported [46,48,49]. Normal lesion growth returned once the Trypanosoma infection was 305 
treated [48]. In one study in squirrel monkeys, L. braziliensis coinfection was shown to block the 306 
increase in QRS interval, i.e. the depolarisation time of the cardiac ventricles, that is normally 307 
associated with T. cruzi infection. This finding led the authors to suggest that prior infection with 308 
Leishmania parasites might provide some protection against Chagas-related cardiopathy [46]. One 309 
human immunological study focused on T-cell responses and showed that TL patients coinfected 310 
with T. cruzi had a higher T-cell differentiation profile than patients with TL only [44]. 311 
 312 
Toxoplasma. Experimental studies in mice suggest that toxoplasmosis affects the course of 313 
leishmaniasis and vice versa [51,52]. Albino mice that were infected first with L. major and 30 to 70 314 
days later with Toxoplasma gondii developed more severe forms of leishmaniasis than mice 315 
infected with L. major alone [51]. By contrast, the course of toxoplasmosis was more benign in 316 
coinfected mice than in those infected with Toxoplasma alone [51]. Another study showed a 317 
different type of interaction. Here, BALB/c mice were experimentally infected first with T. gondii 318 
and five days later with L. major. The acute toxoplasmosis induced a strong Th1 response, and the 319 
BALB/c mice that are normally susceptible to leishmaniasis developed a level of resistance 320 
comparable to that of C57BL/6 mice [52]. In human patients, such positive or negative interactions 321 
between toxoplasmosis and TL have not been reported yet, although one in vitro study found that 322 
T. gondii-specific T cells are recruited into L. braziliensis lesions and could influence TL pathogenesis 323 
locally [50]. 324 
 325 
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Plasmodium. Seven experimental studies assessed Plasmodium coinfection and TL [53-59]. In 326 
coinfection models of P. yoelii or P. berghei together with L. enrietti, L. mexicana or L. amazonensis 327 
in hamsters, C57BL/6 mice, and BALB/c mice, the coinfected animals had larger lesions than the 328 
animals with Leishmania infection only. There was also an adverse effect of leishmaniasis on the 329 
course of malaria, as coinfected animals had increased parasitaemia and mortality compared to 330 
animals with Plasmodium infection only [53-58]. These effects may vary according to the 331 
Leishmania species, because one study of P. yoelii in BALB/c mice reported different findings for L. 332 
amazonensis and L. braziliensis [59]. 333 
 334 
Sporothrix. Coinfection with Sporothrix may occur when fungal spores are inoculated in a TL lesion. 335 
In Colombia, it was suggested that such inoculations occur when people lance their TL lesions using 336 
Sporothrix-contaminated thorns [60]. There is also a case report linking coinfection with Sporothrix 337 
to traumatic injury and TL reactivation (Koebner phenomenon) [61].  338 
 339 
Mycobacterium tuberculosis. We found nine studies (eight case reports and one cross-sectional 340 
study) describing 12 human patients with concurrent tuberculosis and TL (table 1). Five out of these 341 
twelve patients had mucosal forms of TL and four had other, non-localised forms; the type of TL 342 
was not described in three patients. Results of leishmanin skin tests (arguably an in vivo correlate of 343 
Th1 responses) were available for six coinfected patients: five were positive or strongly positive. 344 
More detailed analyses of T-cell responses were not performed. Some authors hypothesised that an 345 
episode of tuberculosis can trigger reactivation of latent leishmaniasis [65,67-69]. Others suggested 346 
that an underlying immune defect could lead to the development of several infectious diseases at 347 
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the same time [70]. This was based on the study of one patient who had lepromatous leprosy, 348 
several leishmaniasis lesions, and miliary tuberculosis, and in whom a reduced responsiveness to IL-349 
12 was found [70].  350 
 351 
Mycobacterium leprae. The search retrieved 12 case reports/series of human patients with 352 
concurrent leprosy and TL, but none of them contained evidence of a significant interaction 353 
between the two infections. Leprosy and TL are both caused by obligate intracellular organisms and 354 
involve a broad spectrum of clinical, histopathological, and immunological manifestations [6,70,73-355 
83]. The paucibacillary/pauciparasitic type of disease (tuberculoid leprosy and localised cutaneous 356 
leishmaniasis) is at one pole of the spectrum and reflects effective T-cell immunity. At the other 357 
pole of the spectrum is the multibacillary/multiparasitic type of disease (lepromatous leprosy and 358 
diffuse cutaneous leishmaniasis), which occurs when the antigen-specific T-cell response is 359 
depressed [70,82-83].  360 
We found descriptions of five patients with lepromatous leprosy and localised TL [74,75,77-361 
79]. In one of these cases, a man with lepromatous leprosy and mucosal leishmaniasis, skin reaction 362 
ĂŶĚ/&EɶƉƌŽĚƵĐƚŝŽŶĂŐĂŝŶƐƚLeishmania antigens were strong whereas the responses against M. 363 
leprae antigens were almost absent [78,79]. Therefore, despite the similarities in the pathogenesis 364 
of TL and leprosy, patients can have a divergent T-cell response to each pathogen, indicating a 365 
degree of compartmentalisation of T-cell immunity. Nonetheless, follow-up of one patient 366 
suggested that IL-10-mediated regulatory responses induced during leprosy may help control the 367 
immunopathology of mucosal leishmaniasis [78,79]. Twenty other patients described in the 368 
literature had disease manifestations of leprosy and TL that were not that far apart on the disease 369 
spectrum [6,70,73,74,76,80-82].  370 
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In addition to these naturally occurring combinations of TL and leprosy, we found 371 
descriptions of artificially induced coinfection [83,84]. In the 1950s and 1960s, it was common 372 
practice in some Leishmania-endemic areas to immunise people against leishmaniasis by the 373 
inoculation of live L. tropica ƉĂƌĂƐŝƚĞƐ ? ?leishmanisation ? ? ?dǁŽƉĂƉĞƌƐƌĞƉŽƌƚŽŶƚŚĞĐůŝŶŝĐĂůĂŶĚ374 
histopathological evolution of 24 Israeli patients with lepromatous leprosy who received a 375 
vaccination with living Leishmania parasites. Twenty-three patients showed the classical clinical 376 
progression of cutaneous leishmaniasis at the site of inoculation. The authors suggested that this 377 
clinical response to vaccination was similar to that of people without leprosy [83]. One additional 378 
patient with lepromatous leprosy, described in a separate report, developed diffuse leishmaniasis 379 
after vaccination, but also in this person, the lesions healed spontaneously. These observations also 380 
suggest that leprosy does not alter the course of TL or vice versa [84]. 381 
 382 
Implications of TL coinfections for clinical practice 383 
Clinical similarities complicating diagnosis. A first diagnostic challenge occurs when there are 384 
clinical similarities between the lesions caused by Leishmania and some other pathogens. When 385 
one aetiological diagnosis is well established, a clinician may be tempted to attribute all the 386 
ƉĂƚŝĞŶƚ ?ƐůĞƐŝŽŶƐƚŽƚŚŝƐŽŶĞŝŶĨĞĐƚŝŽŶĂŶĚƐƚŽƉĞǆĂŵŝŶŝŶŐƚŚĞƉĂƚŝĞŶƚĨŽƌƐǇŵƉƚŽŵƐĂŶĚƐŝŐŶƐŽĨ387 
other diseases. This may happen for instance in patients with concurrent leprosy and leishmaniasis, 388 
particularly when patients have many skin lesions [82]. Furthermore, two case reports describe a 389 
year-long delay in the diagnosis of mucosal leishmaniasis because nasal symptoms were first 390 
attributed to leprosy [77,78]. Mucosal leishmaniasis can also be confused with mucosal 391 
manifestations of tuberculosis. Several authors have emphasised the importance of examining 392 
multiple samples from different skin lesions when coinfection is suspected [73-75,82]. Diagnosis of 393 
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coinfection can become particularly challenging when more than one pathogen is present within 394 
the same lesion. Leishmania parasites have been found in skin or mucosal lesions together with 395 
Sporothrix schenckii, Cryptococcus laurentii, Mycobacterium tuberculosis, Mycobacterium leprae 396 
and Mycobacterium ulcerans [6,60,61,64,65,85].  397 
 398 
Biological similarities complicating diagnosis. A second diagnostic challenge stems from the 399 
biological similarities between Leishmania parasites and other pathogens. This problem is well 400 
documented for Leishmania and T. cruzi, which are both kinetoplastid protozoa with antigenic 401 
similarities. When conventional serological tests are used for the diagnosis of Chagas disease, there 402 
is a problem of cross-reactivity with Leishmania. There have been several attempts to develop 403 
serological tests that differentiate Leishmania from T.cruzi infections [38,39,41,42] and to evaluate 404 
their diagnostic performance in settings where both pathogens are endemic [42,43]. Tests using 405 
purified or recombinant specific antigens of T. cruzi, such as Ag163B6, Ag162B6/cruzipain, or shed 406 
acute phase antigen (SAPA) proved to be useful to identify true coinfections [41,42].  407 
 408 
Issues with the interpretation of diagnostic test results. One Brazilian study found that 52 out of 409 
107 patients with a definite diagnosis of sporothrichosis also had one or more positive 410 
immunological test results for leishmaniasis (leishmanin skin test, ELISA or indirect 411 
immunofluorescence test) [62]. The diagnosis of TL could not be confirmed in this study, as 412 
parasitological confirmation tests were negative (n=24) or not done (n=28). It was, therefore,  not 413 
possible to distinguish between true coinfections, serological cross-reactions, or false-positive 414 
results of the leishmanin skin test due to an allergy to the diluent [62]. The authors emphasise that 415 
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in such a setting, incorrect diagnoses of TL are possible in patients with sporotrichosis, and that 416 
even in the presence of suggestive clinical and epidemiological arguments together with positive 417 
immunological test results for TL, parasitological confirmation is still needed before patients are 418 
exposed to a toxic and possibly unnecessary TL treatment [62].  419 
 420 
Treatment sequence. The first therapeutic challenge in patients with coinfection is to determine 421 
the best sequence of the different treatments. As helminth coinfection appears to increase the time 422 
to healing in patients with cutaneous leishmaniasis [5,12], it seems logical to assume that prompt 423 
diagnosis and treatment of helminth infections may improve the outcome of TL treatment. One 424 
randomised, double-blind, placebo-controlled trial in Bahia, Brazil, examined early versus deferred 425 
treatment of helminth coinfection [22]. This trial enrolled 90 patients with cutaneous leishmaniasis 426 
(most probably caused by L. braziliensis) and helminth coinfection (mainly hookworms, Trichuris 427 
trichiura, Ascaris lumbricoides, Schistosoma mansoni and Strongyloides stercoralis). All participants 428 
were treated with intravenous antimony at 20 mg/kg/day for 20 days. The treatment group also 429 
received triple antihelminthic therapy with albendazole, ivermectin and praziquantel at days 0 and 430 
30, and placebo at day 60. The control group received placebo at days 0 and 30, and specific 431 
antihelminthic therapy based on stool test results on day 60. There was no significant difference 432 
between the two groups in the time to healing of the skin lesions: the median time to cure was 98 433 
days in the treatment group and 88 days in the control group [22].  434 
 435 
Treatment side effects. When two infections are treated at the same time, the drug combinations 436 
may lead to increased intolerance or adverse effects. The combination of antimony with 437 
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antituberculous drugs is feared, and we found a description of death due to renal failure that was 438 
attributed to the combined treatment [67]. The combination treatment for TL (with pentavalent 439 
antimony) and leprosy (with diaminodiphenyl sulfone + rifampicin + clofazimine) may also produce 440 
considerable side effects [6]. Furthermore, several authors have raised concerns about the use of 441 
antimonial treatment for TL in patients with Chagas disease [40,45]. Pentavalent antimony drugs 442 
are known to prolong QT time and cause arrhythmia; they are therefore contraindicated in patients 443 
with known heart disease. On the one hand, cardiomyopathy is a well-known clinical manifestation 444 
of Chagas disease, and therefore, prudence is called for in patients with Leishmania-Trypanosoma 445 
coinfection [40,45]. 446 
 447 
Unexpected responses to treatment. Some case reports discussed unexpected benefits of one 448 
treatment on two infections. For example, there was a report about a patient with chagasic 449 
cardiomyopathy and TL [45] ?ŵŝŽĚĂƌŽŶĞǁĂƐƵƐĞĚƚŽĐŽŶƚƌŽůƚŚĞƉĂƚŝĞŶƚ ?ƐǀĞŶƚƌŝĐƵůĂƌĂƌƌŚǇƚŚŵŝĂ450 
and seemed to promote the healing of TL. The authors considered that amiodarone could have had 451 
an antileishmanial effect although they could not rule out the possibility that the use of amiodarone 452 
coincided with the healing of TL by chance [45].  453 
 Another interesting case was reported in Colombia [69]. A patient diagnosed with 454 
mucocutaneous leishmaniasis and pulmonary tuberculosis first received treatment for tuberculosis 455 
with rifampin, isoniazid, streptomycin and pyrazinamide, over a period of seven months. The 456 
antimonial treatment was deferred because of concerns about the adverse effects of the 457 
combination of antituberculous and antimonial drugs. Despite the lack of specific antileishmanial 458 
treatment, when assessed three months after the end of antituberculous therapy, the mucosal 459 
lesions were fibrosed, scar tissue was evident, and the patient was biopsy culture-negative. A 460 
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similar observation was reported in Brazil, where the lesions of a patient with diffuse cutaneous 461 
leishmaniasis temporarily improved while receiving antituberculous therapy [66]. Some studies 462 
have suggested that streptomycin, isoniazid, and rifampin may have direct antileishmanial activity 463 
[66]. Alternatively, this response might reflect an interaction between TL and tuberculosis. For 464 
example, reduction of mycobacterial burden may release regulatory pressure within the immune 465 
system that also favours resolution of mucosal lesions, or anti-tuberculous treatment may 466 
(re)activate host protective mycobacteria-specific T cells that cross-react with Leishmania antigens.  467 
 468 
Discussion 469 
Summary of main findings 470 
This is the first comprehensive review of the literature about TL and coinfections other than 471 
HIV. Coinfection adds to the complexity of TL: the outcome of a single Leishmania infection in 472 
humans is difficult to predict and the impact of coinfection on the course of TL is even more 473 
puzzling. Nevertheless, coinfection is clinically relevant, as it is frequent, it can lead to diagnostic 474 
errors and delays, and it can influence the effectiveness of treatment and drug side effects. 475 
Therefore, it is crucial to gain a better understanding of the interaction between TL and other 476 
infectious diseases.  477 
 The frequency of coinfections has been studied mostly in Latin-America so far. There is 478 
relatively good evidence about Trypanosoma cruzi infection in Argentina (an estimated 41% of TL 479 
patients also carry T. cruzi) [36] and about helminthiasis in Brazil (an estimated 14% to 88% of TL 480 
patients also carry helminths) [5,12].  481 
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Several hypotheses have been explored about the mechanisms of interaction between the 482 
different microorganisms, but no clear answers emerge so far from a literature that is scattered and 483 
still developing. Such interactions may involve one or all components of innate immunity coupled 484 
with the complexity of regulatory networks that affect the quality and quantity of the acquired 485 
immune responses (e.g. T-cell subset bias or regulatory cytokine production). Given that TL 486 
pathology is fundamentally an immunopathology reaction, coinfections could paradoxically lead to 487 
exacerbated TL disease by enhancing immune responses against Leishmania parasites in lesions. 488 
The impact of Plasmodium coinfection on TL in animal models is clearly detrimental; the impact of 489 
all other coinfections in animal models or human studies is less clear or less consistent. 490 
 Diagnostic problems occur when concurrent infections cause similar lesions (e.g. TL and 491 
leprosy), when different pathogens are present in the same lesions (e.g. Leishmania and Sporothrix 492 
schenckii), or when crossreactions induced by phylogenetically close pathogens affect the accuracy 493 
of diagnostic tests (e.g. serology for leishmaniasis and Chagas disease). Regarding treatment, some 494 
coinfections seem to reduce the efficacy of antileishmanial drugs (i.e. helminthiasis), and there may 495 
be cumulative adverse effects caused by drugs or drug combinations (e.g. antimonial treatment in 496 
patients with chagasic cardiomyopathy, and combinations of antileishmanial and antimycobacterial 497 
drugs).  498 
 499 
Strengths and limitations 500 
The strengths of this review are the broad search of the literature and the fact that the 501 
reporting follows PRISMA guidelines [21]. On the other hand, because the search strategy had few 502 
restrictions, we retrieved information in heterogeneous formats. As a consequence, we could not 503 
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systematically assess the risk of bias in the individual records and decided to include all the 504 
available information. Most animal studies pre-date the introduction of the ARRIVE (Animals in 505 
Research: Reporting In Vivo Experiments) guidelines for reporting animal research [102]; hence, 506 
issues related to experimental design and the avoidance of bias may not have been explicitly 507 
recorded in the publications reviewed.  508 
Despite the broad search including several databases other than MEDLINE, the retrieved 509 
information was fragmented, and the evidence was insufficient to give firm answers to all the 510 
review questions. For example, all the evidence about TL and malaria came from animal studies 511 
without validation in humans. By contrast, all the information about tuberculosis came from human 512 
case reports with limited information about pathogenesis. In total, only 3 out of the 73 included 513 
records were cohort studies or clinical trials specifically designed to investigate the impact of 514 
coinfection on the course of TL in humans. Furthermore, there was not enough information 515 
available to look into the effect of coinfections on different clinical forms of TL (i.e. localised, 516 
diffuse, disseminated, and mucosal) separately. This is an important limitation because the host 517 
immune responses underlying these different forms of TL are contrasting and may be differentially 518 
modified by coinfections. For example, coinfections that induce a strong pro-inflammatory 519 
response could be beneficial in early cutaneous but detrimental in mucosal leishmaniasis. Finally, 520 
there was almost no information about coinfection in human subjects from Africa or Asia.  521 
Several factors may have contributed to the lack of evidence about coinfections. First, 522 
coinfections tend to get less attention than single infections. Second, TL, as well as many of the 523 
relevant coinfections, are neglected diseases that affect poor populations and are typically under-524 
researched and under-reported. Finally, the complexity of TL together with other infections may 525 
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lead to negative results or findings that are difficult to explain, which may reduce the chance of 526 
publication.  527 
 528 
Implications for future research  529 
From a clinical point of view, several questions remain to be resolved. Even if the 530 
interactions between pathogens are complex, these clinical questions are fairly straightforward. For 531 
each of the coinfecting microorganisms, we need to better document: (i) how frequent it is among 532 
patients with TL in different settings, (ii) whether TL patients with the coinfection fare better or 533 
worse than patients without it, (iii) whether the presence of the coinfection affects the accuracy of 534 
diagnostic tests, and (iv) what is the best way to treat the coinfected patient. With advances in the 535 
development of vaccines for leishmaniasis, including TL, an understanding of how vaccine 536 
responses might be modulated due to coinfection also becomes a question of some significance. 537 
With regard to the interaction between pathogens, additional mechanisms, unexplored in 538 
the literature to date in relation to TL, are worthy of consideration. First, metabolic disturbances 539 
resulting from coinfection may alter the capacity of the immune system to appropriately respond 540 
during TL or vice versa [103,104]. Second, coinfections, in particular with helminths, may lead to a 541 
dysbiosis (i.e. alterations in the development or composition of the microbiota) that consequently 542 
impacts on immune health [97,104,105]. Hence, the answer to how the clinical outcome differs 543 
between single and co-infected patients may not lie in understanding how two specific sets of 544 
immune responses interact, but rather in how these responses are linked via complex regulatory 545 
circuits established and maintained by our commensal microbiota.  546 
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Several elements of the design of future experimental research deserve consideration. First, 547 
it is important to clarify what the outcomes of interest are, i.e. the risk of symptomatic disease, the 548 
time between infection and lesion appearance, the size of the lesion, time to healing, response to 549 
treatment, or risk of metastasis and comorbidities. The impact of coinfections on these different 550 
clinical outcomes may vary. Second, the species, the infective doses, and the timing of Leishmania 551 
and coinfection may also matter. Finally, animal models differ from each other, and they do not 552 
always represent what happens in human coinfection.  553 
 554 
Conclusion 555 
In patients with TL, coinfection with other pathogens may be the rule rather than the 556 
exception. More research is needed to unravel how other infections interfere with the 557 
pathogenesis of TL. It is important that clinicians bear in mind the possibility of coinfection because 558 
this can complicate diagnosis and treatment.  559 
 560 
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PRISMA	checklist	for	the	manuscript	“Tegumentary	leishmaniasis	and	coinfections	other	than	HIV”	
by	Martínez	DY	et	al.	
The	checklist	is	taken	from:		Moher	D,	Liberati	A,	Tetzlaff	J,	Altman	DG,	The	PRISMA	Group	(2009).	
Preferred	Reporting	Items	for	Systematic	Reviews	and	Meta-Analyses:	The	PRISMA	Statement.	PLoS	
Med	6(7):	e1000097.	doi:10.1371/journal.pmed1000097.	More	information	is	available	from	
www.prisma-statement.org.		
The	27	PRISMA	items	are	copied	using	italic	font,	the	way	in	which	we	have	been	addressed	each	of	
these	items	in	our	manuscript	is	described	using	regular,	not-italic	font.		
1.! TITLE	-	Identify	the	report	as	a	systematic	review,	meta-analysis,	or	both.		
We	do	not	claim	that	this	manuscript	is	a	systematic	review	because	our	focus	was	broad	(more	
than	one	review	question)	and	because	the	available	information	was	diverse	(e.g.	different	
types	of	coinfection	and	divergent	study	designs).	Nevertheless,	as	described	below,	we	took	a	
systematic	approach	to	searching	literature,	selecting	records	and	obtaining	information	from	
the	included	records.	The	title	of	the	manuscript	is	“Tegumentary	leishmaniasis	and	coinfections	
other	than	HIV”.	The	fact	that	the	manuscript	is	a	review	is	mentioned	early	in	the	abstract.		
2.! ABSTRACT	-		Provide	a	structured	summary	including,	as	applicable:	background;	objectives;	data	
sources;	study	eligibility	criteria,	participants,	and	interventions;	study	appraisal	and	synthesis	
methods;	results;	limitations;	conclusions	and	implications	of	key	findings;	systematic	review	
registration	number.		
Applicable	elements	are	included	in	the	abstract;	the	review	protocol	was	not	registered.		
3.! INTRODUCTION	-	Describe	the	rationale	for	the	review	in	the	context	of	what	is	already	known.	
People	infected	with	Leishmania	may	carry	other	pathogens	as	well.	These	other	pathogens	may	
alter	the	host	immune	response	against	Leishmania	infection	and	hence	the	clinical	course	of	
leishmaniasis.	The	interaction	between	tegumentary	leishmaniasis	and	HIV	is	well	established	
and	has	been	reviewed	before.	This	is	the	first	comprehensive	review	of	tegumentary	
leishmaniasis	and	coinfections	with	pathogens	other	than	HIV.	
4.! INTRODUCTION	-	Provide	an	explicit	statement	of	questions	being	addressed	with	reference	to	
participants,	interventions,	comparisons,	outcomes,	and	study	design	(PICOS).		
The	focus	of	this	review	is	explained	in	the	last	paragraph	of	the	introduction:	“The	objectives	of	
the	present	review	are	to	summarise	the	evidence	about	the	(i)	frequency	of	tegumentary	
leishmaniasis	(TL)	and	coinfections	other	than	HIV	in	human	populations,	(ii)	interactions	
between	Leishmania	and	other	pathogens	in	animal	models	and	human	subjects,	and	(iii)	
implications	of	TL	coinfections	for	clinical	practice.”	
5.! METHODS	-	Indicate	if	a	review	protocol	exists,	if	and	where	it	can	be	accessed	(e.g.,	Web	
address),	and,	if	available,	provide	registration	information	including	registration	number.	
No	protocol	has	been	registered	for	this	review.	
6.! METHODS	-	Specify	study	characteristics	(e.g.,	PICOS,	length	of	follow-up)	and	report	
characteristics	(e.g.,	years	considered,	language,	publication	status)	used	as	criteria	for	eligibility,	
giving	rationale.		
We	searched	the	medical	literature	to	identify	publications	about	TL	and	coinfections.	To	
identify	coinfections,	we	used	search	terms	indicating	(groups	of)	infections,	pathogens,	and	
diseases	caused	by	these	pathogens.	For	the	purpose	of	this	review,	we	defined	TL	as	all	forms	
of	cutaneous	(localised,	disseminated	or	diffuse)	and	mucocutaneous	leishmaniasis.	Records	
about	the	skin	manifestations	caused	by	L.	donovani	and	L.	infantum/L.	chagasi	were	not	
included	because	the	main	clinical	outcome	of	these	infections	is	visceral	leishmaniasis,	which	is	
outside	the	scope	of	this	review.	Records	about	HIV/AIDS	and	TL	were	not	included	because	this	
topic	has	already	been	extensively	reviewed	elsewhere.	Records	about	the	contamination	or	
superinfection	of	TL	lesions	with	Gram-positive	or	Gram-negative	bacteria	of	the	skin	such	as	
Staphylococcus	aureus	or	Streptococcus	pyogenes	were	also	excluded.	Review	papers	were	not	
included.	We	did	not	restrict	the	search	by	geographical	region,	study	design,	language	of	
publication	or	publication	date.	
7.! METHODS	-	Describe	all	information	sources	(e.g.,	databases	with	dates	of	coverage,	contact	
with	study	authors	to	identify	additional	studies)	in	the	search	and	date	last	searched.	
Information	for	this	review	was	identified	in	August	2017	by	searches	of	MEDLINE,	Embase,	
LILACS,	Scielo,	Cochrane,	African	Index	Medicus,	as	well	as	local	library	databases.	We	also	
reviewed	the	reference	lists	of	selected	articles.	
8.! METHODS	-	Present	full	electronic	search	strategy	for	at	least	one	database,	including	any	limits	
used,	such	that	it	could	be	repeated.		
The	detailed	search	strategy	for	MEDLINE	is	given	in	S1	File.	
9.! METHODS	-	State	the	process	for	selecting	studies	(i.e.,	screening,	eligibility,	included	in	the	
systematic	review,	and,	if	applicable,	included	in	the	meta-analysis).			
One	reviewer	(DYM)	screened	titles	and	abstracts,	and	two	reviewers	(DYM	and	KV)	assessed	
the	eligibility	of	the	full-text	papers	using	the	eligibility	criteria	outlined	above	(item	6).	Doubts	
and	discordances	were	resolved	through	discussion.	
10.!METHODS	-	Describe	method	of	data	extraction	from	reports	(e.g.,	piloted	forms,	independently,	
in	duplicate)	and	any	processes	for	obtaining	and	confirming	data	from	investigators.		
Two	reviewers	(DYM	and	KV)	read	and	summarised	the	included	records.	Doubts	and	
discordances	were	resolved	through	discussion.	We	did	not	contact	investigators	to	obtain	
additional	information	or	to	confirm	data.		
11.!METHODS	-	List	and	define	all	variables	for	which	data	were	sought	(e.g.,	PICOS,	funding	sources)	
and	any	assumptions	and	simplifications	made.		
Specific	points	of	interest	while	reading	and	summarising	the	articles	were:	(i)	frequency	of	
coinfection	in	humans;	(ii)	mechanisms	of	interaction	and	effect	of	coinfection	on	TL	
progression;	and	(iii)	potential	implications	for	clinical	management.	
12.!METHODS	-	Describe	methods	used	for	assessing	risk	of	bias	of	individual	studies	(including	
specification	of	whether	this	was	done	at	the	study	or	outcome	level),	and	how	this	information	is	
to	be	used	in	any	data	synthesis.		
Our	search	did	not	include	restrictions	in	study	design	and	retrieved	information	in	various	
formats.	As	a	consequence,	we	did	not	formally	assess	the	risk	of	bias	of	individual	studies	but	
described	the	different	study	designs	instead.	
13.!METHODS	-	State	the	principal	summary	measures	(e.g.,	risk	ratio,	difference	in	means).		
The	information	was	found	in	heterogeneous	formats.	We	described	the	information	the	same	
way	the	authors	of	the	original	publications	did,	using	counts,	proportions	and	medians.		
14.!METHODS	-	Describe	the	methods	of	handling	data	and	combining	results	of	studies,	if	done,	
including	measures	of	consistency	(e.g.,	I2)	for	each	meta-analysis.		 	
This	review	does	not	include	a	meta-analysis.	
15.!METHODS	-	Specify	any	assessment	of	risk	of	bias	that	may	affect	the	cumulative	evidence	(e.g.,	
publication	bias,	selective	reporting	within	studies).		 	
Not	done	
16.!METHODS	-	Describe	methods	of	additional	analyses	(e.g.,	sensitivity	or	subgroup	analyses,	
meta-regression),	if	done,	indicating	which	were	pre-specified.		
Not	done	
17.!RESULTS	-	Give	numbers	of	studies	screened,	assessed	for	eligibility,	and	included	in	the	review,	
with	reasons	for	exclusions	at	each	stage,	ideally	with	a	flow	diagram.	
The	MEDLINE	search	retrieved	3014	records	and	searching	other	databases	yielded	348	
additional	records.	After	reading	titles	or	abstracts	or	both,	we	removed	382	duplicates	and	
discarded	2853	records	because	they	were	not	relevant	(Fig	1).	The	most	frequent	reason	for	
dropping	records	was	that	while	leishmaniasis	and	another	infection	were	mentioned	in	the	
same	text,	the	publication	was	not	about	coinfection	(e.g.	a	paper	about	different	infections	
occurring	in	the	same	region	but	not	affecting	the	same	persons).	We	assessed	the	remaining	
127	full-text	records	for	eligibility	and	retained	71	for	the	present	review	(Fig	1).	
18.!RESULTS	-	For	each	study,	present	characteristics	for	which	data	were	extracted	(e.g.,	study	size,	
PICOS,	follow-up	period)	and	provide	the	citations.		
Table	1	gives	an	overview	of	all	the	included	studies.	This	table	describes	according	to	the	
coinfecting	pathogen	and	the	study	design:	the	number	of	included	studies,	the	number	of	
human	cases	with	coinfection,	and	the	citations.		
19.!RESULTS	-	Present	data	on	risk	of	bias	of	each	study	and,	if	available,	any	outcome	level	
assessment	(see	item	12).		
Study	design	is	described	instead	of	risk	of	bias:	the	71	articles	included	in	this	review	had	
different	study	designs.	There	were	21	original	research	papers	about	experimental	studies	of	
coinfection	in	animals,	and	50	original	research	papers	about	coinfection	in	human	patients.	The	
50	studies	about	human	subjects	included	1	clinical	trial,	2	cohort	studies,	13	cross-sectional	or	
prevalence	studies,	7	studies	on	the	development	or	performance	of	diagnostic	tests,	22	case	
series	or	case	reports	with	a	clinical	focus,	and	5	case	series	or	reports	with	an	immunological	
focus.	
20.!RESULTS	-	For	all	outcomes	considered	(benefits	or	harms),	present,	for	each	study:	(a)	simple	
summary	data	for	each	intervention	group	(b)	effect	estimates	and	confidence	intervals,	ideally	
with	a	forest	plot.		
Main	findings	are	summarised	following	a	different	structure:	frequency	of	TL	coinfections	in	
human	populations;	interactions	between	Leishmania	and	other	pathogens,	and	Implications	of	
TL	coinfections	for	clinical	practice.	
21.!RESULTS	-	Present	results	of	each	meta-analysis	done,	including	confidence	intervals	and	
measures	of	consistency.		
Not	done	
22.!RESULTS	-	Present	results	of	any	assessment	of	risk	of	bias	across	studies	(see	Item	15).		
Not	done	
23.!RESULTS	-	Give	results	of	additional	analyses,	if	done	(e.g.,	sensitivity	or	subgroup	analyses,	
meta-regression	[see	Item	16]).		
Not	done	
24.!DISCUSSION	-	Summarize	the	main	findings	including	the	strength	of	evidence	for	each	main	
outcome;	consider	their	relevance	to	key	groups	(e.g.,	healthcare	providers,	users,	and	policy	
makers).		
The	discussion	contains	a	specific	section	entitled	‘summary	of	main	findings’.	
25.!DISCUSSION	-	Discuss	limitations	at	study	and	outcome	level	(e.g.,	risk	of	bias),	and	at	review-
level	(e.g.,	incomplete	retrieval	of	identified	research,	reporting	bias).		
The	discussion	contains	a	specific	section	entitled	‘strengths	and	limitations’.	
26.!DISCUSSION	-	Provide	a	general	interpretation	of	the	results	in	the	context	of	other	evidence,	and	
implications	for	future	research.		
The	discussion	contains	a	specific	section	entitled	‘implications	for	future	research’.		
27.!FUNDING	-	Describe	sources	of	funding	for	the	systematic	review	and	other	support	(e.g.,	supply	
of	data);	role	of	funders	for	the	systematic	review.	
DYM	received	a	PhD	scholarship	from	the	Belgian	Directorate	General	for	Development	
Cooperation	(third	framework	agreement,	project	95502).	The	funders	had	no	role	in	study	
design,	data	collection	and	analysis,	decision	to	publish,	or	preparation	of	the	manuscript.	
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